Regeneron’s experimental antibody cocktail will be evaluated in a phase 3 trial coordinated by researchers at the University of Oxford as a prospective remedy for patients hospitalized by COVID-19.
The cocktail of anti-viral antibodies, REGN-COV2, will be evaluated in the RECOVERY trial in patients hospitalized by COVID-19, and the full study will compare the effects of adding the cocktail to the same traditional treatment rather than the popular – treatment alone.
REGN-COV2, which was designed in particular as a COVID-19 therapy, is recently being studied in two other phase 2/3 studies for the remedy of the new disease. Regeneron is also testing the drug in a Phase 3 trial for the prevention of COVID-19 in the circle of family contacts in inflamed individuals.
The Phase 3 prevention trial is expected to be conducted at approximately one hundred sites in the United States and will recruit approximately 2,000 patients to assess the prestige of SARS-CoV-2 infection. At the same time, the two Phase 2/3 healing trials are expected to be conducted at approximately 150 sites in the United States, Brazil, Mexico and Chile, and virological and clinical parameters will be compared.
In preclinical studies, the antibody cocktail could possibly have protected against COVID-19-related viral exhaust mutations, and prevention and treatment studies in non-human primates have also shown that the cocktail can decrease the amount of virus and related lung damage. . .
The drug’s ability to oppose viral leakage is remarkable, as this procedure occurs when the spontaneous mutant bureaucracy of a virus can escape the blocker action of treatment, when that virus is under the strain of that antiviral drug.
This means that REGN-COV2 may also stand against the mutant bureaucracy of the SARS-CoV-2 virus, which causes COVID-19, which can occasionally proliferate and possibly eventually become the dominant strain of the virus.
“The world urgently wants new drugs to combat COVID-19, and well-designed trials to compare the characteristics of new remedies will temporarily help us locate which ones are most effective,” said George D Yancopoulos, President and Chief Scientific Officer of Regeneron.
“REGN-COV2 specially designed by Regeneron scientists to attack the virus guilty of COVID-19. RECOVERY will be the fourth complex randomized clinical trial comparing REGN-COV2 and will expand our wisdom on how this new antibody cocktail can help hospitalized patients who need it. “Added.
In August, Regeneron signed an agreement with Roche for REGN-VOC2’s global production and progression functions. Under the agreement, Regeneron will distribute and record antibody cocktail sales in the United States, while Roche will be guilty of outdoor distribution. United States.
Collaboration is expected to increase the source of REGN-COV2 through at least 3 and one component times its existing capacity, according to Roche. As a component of this agreement, Roche and Regeneron jointly fund and implement the ongoing Phase 3 prevention test, as well as other Phase 1 protection studies.
September 15, 2020
A cocktail will be evaluated in patients hospitalized with COVID-19